News • Microbubbles

Bracco Imaging to innovate ultrasound for new personalized gene therapy

Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced that it has initiated new experimental activities in its R&D Center in Geneva, Switzerland, to explore a new application for gas-filled microbubbles in the development of personalized gene therapy for treatment of chronic dysfunctional diseases related to lipid metabolism.

Source: Pixabay/yancharris

Microbubbles have already revolutionized medical imaging in the field of Contrast Enhanced Ultrasound (CEUS) - a high-sensitivity, non-invasive, real-time, cost-effective and radiation-free modality that improves the visualization and assessment of cardiac cavities, large vessels and tissue vascularity. As an established and robust tool for diagnostic imaging, microbubbles are now also considered a platform for therapeutic drug or gene delivery.

We are looking for a large number of biomedical applications, and are confident that our technology can be used to address a wide range of healthcare challenges

Thierry Bettinger

“Today’s  kick-off of new research activities provides an additional opportunity to exploit the microbubble platform and create an innovative therapeutic approach to addressing unmet medical needs,” said Thierry Bettinger, PhD, Research Department Director at Bracco Suisse SA. “We consider the personalized gene therapy under evaluation as an opportunity to expand the use of the microbubble platform. We are looking for a large number of biomedical applications, and are confident that our technology can be used to address a wide range of healthcare challenges.”

This research project is the result of an agreement that Bracco has recently signed with SonoGene LCC, an innovative start-up company focused on the development of novel platforms for therapeutic delivery of genes and pharmaceuticals using ultrasound-triggered, non-viral microbubble delivery systems. Furthermore, the research project envisages a very close cooperation with Steven Feinstein, MD - Professor of Medicine at Rush University Medical Center in Chicago, Illinois, U.S., and Co-President of the International Contrast Ultrasound Society (ICUS) - who is considered one of the most influential experts in CEUS.

“SonoGene’s early animal studies successfully showed that tiny microbubbles can deliver genes to a targeted organ system and produce a desired therapeutic effect,” Dr. Feinstein said. He explained that the initial studies used microbubbles to transport genes to the liver in order to stimulate the body’s production of natural, de novo HDL cholesterol - the “good cholesterol” that may protect against certain cardiovascular diseases. “SonoGene’s gene therapy can ultimately harness the body’s own biological mechanisms to provide a natural form of therapy,” he added. 

Dr. Feinstein also believes that the microbubbles will provide a broad and flexible platform for safely delivering other genes and pharmaceutical compounds, including cancer drugs, to targeted organ systems or tumors throughout the body. In addition, he noted that microbubble-based delivery vehicles do not use viral carriers, synthetic or recombinant proteins. “Our investments to exploit innovative approaches of the microbubble platform reinforce our commitment and leadership in ultrasound, while fostering future applications of this technique beyond diagnostic imaging,” said Micol Fornaroli, Chief Strategy Officer at Bracco Imaging. “SonoGene is excited to collaborate with Bracco Imaging and leverage our unique and extensive expertise in the development of microbubble-based gene and drug delivery systems to save lives and improve patient care,” said Dr. Eric Coles, Chief Executive Officer at SonoGene.

Source: Bracco Imaging


Read all latest stories

Related articles


Article • CEUS

Advancing contrast enhanced ultrasound

The ability to demonstrate blood perfusion as well as organ function using contrast agentenhanced ultrasound is quickly finding innovative uses in clinical practice. Contrast-enhanced ultrasound…


Article • Gadolinium-based contrast agents

Clinicians define optimal approach for MRI contrast to maximize benefit

Gadolinium-based contrast agents are an essential component of MRI exams, but are challenged by findings of residual depositions of gadolinium in the body, even though the clinical relevance remains…


Article • Contrast enhancement

Sonic boom with bubbles

Illuminating blood vessels, opening the blood-brain barrier and delivering drugs. What will be the next big thing that tiny microbubbles can do?

Related products

Subscribe to Newsletter